Dupilumab, a human monoclonal IgG4 antibody targeting the alpha subunit of IL-4 receptor, is probably the most promising systemic therapy for AD, as inhibiting the IL-4 and IL-13 signaling pathways is an efficient mechanism for controlling the Th2 response [7,160]. This evidence concerns the gene IL4 and Alzheimer disease.